-
公开(公告)号：US20240343808A1
公开(公告)日：2024-10-17
申请号：US18392954
申请日：2023-12-21
发明人： Gordon James Freeman , Arlene Helen Sharpe , Gerhard Johann Frey , Hwai Wen Chang , Jennifer Marie Mataraza , Glenn Dranoff
IPC分类号： C07K16/28 , A61K39/00 , A61K39/395 , A61K45/06 , A61N5/10 , C07K16/30 , G01N33/574
CPC分类号： C07K16/2827 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61N5/10 , C07K16/30 , C07K16/3023 , C07K16/3046 , C07K16/3053 , C07K16/3069 , G01N33/57492 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , G01N2333/70532
摘要： Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
-
公开(公告)号：US12109212B2
公开(公告)日：2024-10-08
申请号：US16550993
申请日：2019-08-26
发明人： William C. Hahn , Joseph Rosenbluh
IPC分类号： A61K31/506 , A61K45/06 , C07K14/47 , C12N15/113 , G01N33/50
CPC分类号： A61K31/506 , A61K45/06 , C07K14/47 , C07K14/4702 , C07K14/4747 , C12N15/1135 , G01N33/5017 , C12N2310/14 , C12N2310/3233 , C12N2310/531 , G01N2500/10
摘要： The present invention provides methods of treating a subject having a Wnt/beta-catenin active cancer by administering to said subject a compound that inhibits the expression or activity of YES1, BIRC5 or BCL2L1, a compound that inhibits YAP1-beta-catenin complex formation, a compound that inhibits YAP1-beta-catenin complex binding to DNA, a compound that inhibits YAP1-beta-catenin-TBX5 complex formation, or any combination thereof. The compound can be, for example, a nucleic acid, a peptide, an antibody or a small molecule. Methods of screening for therapeutic targets for treating cancer are included.
-
公开(公告)号：US12076390B2
公开(公告)日：2024-09-03
申请号：US17405748
申请日：2021-08-18
发明人： Wayne A. Marasco
IPC分类号： A61K39/145 , A61P31/16 , C07K16/10 , A61K39/00
CPC分类号： A61K39/145 , A61P31/16 , C07K16/1018 , A61K2039/505 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/732 , C07K2317/76 , C07K2317/92
摘要： The present invention provides structural determinants important for binding to the stem domain of the HA protein of influenza virus, and methods of use thereof for production of high affinity neutralizing influenza virus antibodies based upon these determinants. The present invention further provides tools for determining the efficacy of an influenza virus vaccine. The present invention further provides a molecular signature useful for determining the efficacy of an influenza virus vaccine in a subject, or for predicting prior immunologic exposure or antigen responsiveness to vaccine or influenza virus infection.
-
公开(公告)号：US12054787B2
公开(公告)日：2024-08-06
申请号：US18047910
申请日：2022-10-19
发明人： Xiaole Liu , Peng Jiang
IPC分类号： C12Q1/6886
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158
摘要： The present invention relates to gene expression signatures that predict response and resistance to targeted therapy and immunotherapy.
-
5.发明授权公开(公告)号：US12053476B2
公开(公告)日：2024-08-06
申请号：US17161612
申请日：2021-01-28
申请人： BAYER PHARMA AKTIENGESELLSCHAFT , THE BROAD INSTITUTE, INC. , DANA-FARBER CANCER INSTITUTE, INC.
发明人： Timothy A. Lewis , Alex Burgin , Monica Schenone , Xiaoyun Wu , Heidi Greulich , Matthew Meyerson , Luc De Waal , Antje Margret Wengner , Knut Eis , Philip Lienau , Ulrike Sack , Martin Lange
IPC分类号： A61K31/5377 , A61K31/50 , A61P35/00 , C07D413/10
CPC分类号： A61K31/5377 , A61K31/50 , A61P35/00 , C07D413/10
摘要： The present invention features improved compounds, especially
methods of identifying patients having cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein).-
6.发明公开公开(公告)号：US20240245786A1
公开(公告)日：2024-07-25
申请号：US18269122
申请日：2021-12-22
发明人： Nathanael S. Gray , Tinghu Zhang , Lewis C. Cantley , Sindhu Carmen Sivakumaren , Theresa Manz , Eric Wang , Wenzhi Ji , Eric S. Fischer , Katherine Donovan
IPC分类号： A61K47/55 , A61K31/506 , C07D401/14 , C07D417/14
CPC分类号： A61K47/55 , A61K31/506 , C07D401/14 , C07D417/14
摘要： The present invention relates to bifunctional compounds, compositions, and methods for treating diseases or conditions by modulating (e.g., reducing) the level or activity of at least one of PIP4K2A, PIP4K2B, and PIP4K2C.
-
7.发明授权公开(公告)号：US12042513B2
公开(公告)日：2024-07-23
申请号：US17093832
申请日：2020-11-10
发明人： Jeremiah A. Johnson , Hung Vanthanh Nguyen , Yivan Jiang , Alexandre Detappe , Michael Agius , Irene Ghobrial , XueZhou Wang
IPC分类号： A61K31/795 , A61K47/55 , A61K47/60 , C07D495/14 , C08G61/08 , C08G65/00
CPC分类号： A61K31/795 , A61K47/55 , A61K47/60 , C07D495/14 , C08G61/08 , C08G65/00
摘要： Disclosed multifunctional compounds, conjugates, macromolecules, and polymers that target dysregulated proteins for degradation. Also disclosed are methods of preparation, compositions, kits, and methods of use relating to the degraders.
-
8.发明公开公开(公告)号：US20240217970A1
公开(公告)日：2024-07-04
申请号：US18287347
申请日：2022-04-28
发明人： Tinghu Zhang , Lyn Howard Jones , Hu Liu , Jianwei Che
IPC分类号： C07D471/04 , A61K31/437 , A61K31/444 , C07D401/14 , C07D405/14
CPC分类号： C07D471/04 , A61K31/437 , A61K31/444 , C07D401/14 , C07D405/14
摘要： Disclosed are compounds and pharmaceutically acceptable salts and stereoisomers thereof that may bind to CRBN complex and cause degradation of various proteins e.g., IKZF2 (Helios). Also disclosed are pharmaceutical compositions containing same, and methods of making and using the compounds to treat diseases and disorders characterized or mediated by the presence of a protein, and hence would benefit from degradation of said protein.
-
公开(公告)号：US12023308B2
公开(公告)日：2024-07-02
申请号：US17494824
申请日：2021-10-05
申请人： THE BROAD INSTITUTE, INC. , THE BRIGHAM & WOMEN'S HOSPITAL, INC. , DANA-FARBER CANCER INSTITUTE, INC. , Instituto Carlos Slim de la Salud, A.C.
发明人： Anna Greka , Moran Dvela-Levitt , Maria Alimova , Eric Lander , Todd R. Golub , Florence Wagner , Brian Chamberlain , Valeria Padovano , Joseph Growney
IPC分类号： A61K31/13 , A61P13/12 , A61P27/02 , C12Q1/6883
CPC分类号： A61K31/13 , A61P13/12 , A61P27/02 , C12Q1/6883
摘要： The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of proteinopathies, particularly MUC1-associated kidney disease (ADTKD-MUC1 or MKD), Retinitis Pigmentosa (e.g., due to rhodopsin mutations), autosomal dominant tubulo-interstitial kidney disease due to UMOD mutation(s) (ADTKD-UMOD), and other forms of toxic proteinopathies resulting from mutant protein accumulation in the ER or other secretory pathway compartments and/or vesicles, among others. The disclosure also identifies and provides TMED9-binding agents as capable of treating or preventing proteinopathies of the secretory pathway, and further provides methods for identifying additional TMED9-binding agents.
-
公开(公告)号：US20240197678A1
公开(公告)日：2024-06-20
申请号：US18281861
申请日：2022-03-18
发明人： Inchul You , Nathanael S. Gray , Tinghu Zhang , Sirano Dhe-Paganon , Nir London , Christian Dubiella
IPC分类号： A61K31/381 , A61K31/506 , A61K31/519 , C07D333/48
CPC分类号： A61K31/381 , A61K31/506 , A61K31/519 , C07D333/48
摘要： Disclosed are compounds which inhibit Pin1 activity, methods of making the compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds to treat diseases or disorders characterized or mediated by dysregulated Pin1 activity.
-
-
-
-
-
-
-
-
-
搜索结果
1671 条记录 (耗时 0.044 秒)
